Search results
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in female patients with severe aortic stenosis.Dr Didier Tchétché (Clinique Pasteur, FR) joins us onsite at TCT Conference to discuss the pooled findings from the RHEIA (NCT04160130) and PARTNER 3 (NCT02675114) trials.RHEIA and PARTNER 3 are…
View more
Innovation and Development of PHV TAVR
Added:
4 months ago
Review Article
Added:
1 year ago
EuroPCR 24 - We are joined onsite by Prof Ole De Backer (Rigshospitalet, DK) to discuss the findings from the NOTION-2 Study. (NCT02825134).NOTION-2 is a randomized, multicenter trial which aimed to investigate transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in 376 patients under 75 years of age with severe aortic valve stenosis in regard to intra-…
View more
Added:
1 year ago
ACC.24 — Investigator Dr Moritz Seiffert (University Heart and Vascular Center Hamburg, DE) joins us onsite at ACC to discuss the findings of the DEDICATE-DZHK6 Trial (NCT03112980).This randomized controlled, multi-center trial aimed to investigate whether transcatheter aortic valve implantation (TAVI) is non-inferior to surgical aortic valve replacement (SAVR) in patients with symptomatic severe…
View more
Added:
6 months ago
Explore comprehensive lifetime management strategies for aortic stenosis with Dr Samineh Sehatbakhsh, addressing the evolving landscape of treatment options for patients across all risk categories.This detailed presentation, part of the Complex Cases track, examines the critical decision-making process between TAVR and surgical aortic valve replacement in the modern era. Dr Sehatbakhsh addresses…
View more
Added:
11 months ago
CRT 25 - Dr S. Chris Malaisrie (Northwestern University, Evanston, US) joins us to discuss the five-year outcomes from the PARTNER 3 aortic valve-in-valve registry (NCT02675114). The prospective, randomized, multi-center study aimed to assess TAVR with the Edwards SAPIEN 3 transcatheter heart valve (Edwards Lifesciences) compared to aortic valve replacement with a commercially available surgical…
View more
Added:
4 months ago
Explore advanced strategies for preventing and managing LVOT obstruction in transcatheter mitral valve replacement with Dr Mackram EleidThis presentation, part of Women As One's comprehensive Structural Interventions track, examines of a 90-year-old patient with severe mitral annular calcification, heart failure with preserved ejection fraction, and significant basal septal hypertrophy. Dr Eleid…
View more
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451)…
View more
Added:
2 days ago
Source:
Transcatheter Academy
Seven-year follow-up data from the PARTNER 3 trial shows no significant difference in key outcomes between transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement (SAVR) for low-risk patients with severe, symptomatic aortic stenosis.¹ This long-term assessment provides further insight into valve durability and clinical outcomes, building on previous 5-year data which…
View more
Added:
9 months ago
EuroPCR 25 - First-in-human outcomes from the TRiCares Topaz Tricuspid Valve Replacement System in patents with tricuspid regurgitation (TR) show positive performance results and improved safety.We are joined by Dr Julien Dreyfus (Centre Cardiologique du Nord, Saint-Denis, FR) to discuss outcomes from the first-in-human, pivotal, multi-centre TRICURE EU study (NCT06581471; TRiCares) investigating…
View more